{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:47:11Z","timestamp":1793083631438,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01441-3","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:24:17Z","timestamp":1767169457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-116X","authenticated-orcid":false,"given":"Kenneth J. C.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9933","authenticated-orcid":false,"given":"Ricardo","family":"Parrondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"De Menezes Silva Corraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin","family":"Carabenciov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephens","family":"Haily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udit","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Wiedmeier-Nutor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Zekeridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"1441_CR1","doi-asserted-by":"publisher","first-page":"71. e1","DOI":"10.1016\/j.jtct.2024.12.002","volume":"31","author":"M Ellithi","year":"2025","unstructured":"Ellithi M, Elsallab M, Lunning MA, Holstein SA, Sharma S, Trinh JQ, et al. Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data. Transplant Cell Ther. 2025;31:71. e1\u2013e14.","journal-title":"Transplant Cell Ther"},{"key":"1441_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"1441_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, G\u00e1llego P\u00e9rez-Larraya J, van de Donk NW, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:32.","journal-title":"Blood Cancer J"},{"key":"1441_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145:85\u201397.","journal-title":"Blood"},{"key":"1441_CR5","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2023-178743","volume":"142","author":"NWCJ Van De Donk","year":"2023","unstructured":"Van De Donk NWCJ, Sidana S, Schecter JM, Jackson CC, Lendvai N, De Braganca KC, et al. Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and cartitude-4 studies of ciltacabtagene autoleucel (Cilta-cel). Blood. 2023;142:3501.","journal-title":"Blood"},{"key":"1441_CR6","doi-asserted-by":"publisher","first-page":"S503","DOI":"10.1016\/j.jtct.2025.01.801","volume":"31","author":"EC Fitzgerald","year":"2025","unstructured":"Fitzgerald EC, Gilbert DL, Tanner A, Lin Y, Gupta S. Orthopnea from phrenic nerve palsy after ciltacabtagene autoleucel CAR-T in a patient with multiple myeloma. Transplant Cell Ther. 2025;31:S503.","journal-title":"Transplant Cell Ther"},{"key":"1441_CR7","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.2023020571","volume":"142","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Miller KC, Yee AJ, Rejeski K, Johnson PC, Raje N, et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood. 2023;142:1243\u20138.","journal-title":"Blood"},{"key":"1441_CR8","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of Parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27:2099\u2013103.","journal-title":"Nat Med"},{"key":"1441_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1441_CR10","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations the Movement Disorder Society Task Force on rating scales for Parkinson\u2019s disease. Mov Disord. 2004;19:1020\u20138.","journal-title":"Mov Disord"},{"key":"1441_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/01.STR.0000258355.23810.c6","volume":"38","author":"JL Banks","year":"2007","unstructured":"Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke. 2007;38:1091\u20136.","journal-title":"Stroke"},{"key":"1441_CR12","unstructured":"mSMART. The Risk Adapted Approach to Management of Multiple Myeloma and Related Disorders: Management of CAR-T associated cytokine release syndrome (CRS), neurotoxicity, and cytopenias [2025 Apr 04]. Available from: https:\/\/www.msmart.org\/mm-treatment-guidelines."},{"key":"1441_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"1441_CR14","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Berdeja JG, Madduri D, Jakubowiak AJ, Agha ME, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed\/refractory multiple myeloma (R\/R MM): Updated results from CARTITUDE-1. Wolters Kluwer Health; 2021.","DOI":"10.1016\/j.htct.2021.10.460"},{"key":"1441_CR15","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/blood-2024-203007","volume":"144","author":"B Paiva","year":"2024","unstructured":"Paiva B, Manrique I, Thompson EG, Campbell TB, Guerrero C, Martin N, et al. Biological and clinical significance of endogenous and chimeric antigen receptor (CAR) T cell immune profiling in relapsed\/refractory multiple myeloma (RRMM) patients. Blood. 2024;144:900.","journal-title":"Blood"},{"key":"1441_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1182\/blood-2024-212135","volume":"144","author":"J Gustine","year":"2024","unstructured":"Gustine J, Cirstea D, Branagan AR, Yee AJ, Maus M, Frigault MJ, et al. Previous HDM\/ASCT adversely impacts PFS with BCMA-Directed CAR T-Cell therapy in multiple myeloma. Blood. 2024;144:79.","journal-title":"Blood"},{"key":"1441_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","volume":"23","author":"NG Holtzman","year":"2021","unstructured":"Holtzman NG, Xie H, Bentzen S, Kesari V, Bukhari A, El Chaer F, et al. Immune effector cell\u2013associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro-Oncol. 2021;23:112\u201321.","journal-title":"Neuro-Oncol"},{"key":"1441_CR18","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1182\/bloodadvances.2023012470","volume":"8","author":"M Mejia Saldarriaga","year":"2024","unstructured":"Mejia Saldarriaga M, Pan D, Unkenholz C, Mouhieddine TH, Velez-Hernandez JE, Engles K, et al. Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma. Blood Adv. 2024;8:3859\u201369.","journal-title":"Blood Adv"},{"key":"1441_CR19","first-page":"S215","volume":"31","author":"J Turner","year":"2025","unstructured":"Turner J, Forsberg PA, Nicholson S, Schade H, Matous J, Gregory TK. Prophylactic Dexamethasone Rescues Unrestrained Lymphocyte Expansion in Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma. Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther. 2025;31:S215\u2013S6.","journal-title":"Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther"},{"key":"1441_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bjh.17673","volume":"195","author":"MS Topp","year":"2021","unstructured":"Topp MS, van Meerten T, Houot R, Minnema MC, Bouabdallah K, Lugtenburg PJ, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;195:388\u201398.","journal-title":"Br J Haematol"},{"key":"1441_CR21","doi-asserted-by":"publisher","first-page":"v68","DOI":"10.1093\/neuonc\/noae144.223","volume":"26","author":"JA Gudera","year":"2024","unstructured":"Gudera JA, Baehring JM, Fulbright RK, Dietrich J, Karschnia P. P12.10.b hypokinetic movement disorders following adoptive immunotherapy with BCMA-directed CAR T-cells: a consecutive case series. Neuro-Oncol. 2024;26:v68\u2013v.","journal-title":"Neuro-Oncol"},{"key":"1441_CR22","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1182\/blood.2024028172","volume":"145","author":"V Blumenberg","year":"2025","unstructured":"Blumenberg V, Puliafito BR, Graham CE, Leick MB, Chowdhury MR, King M, et al. Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment. Blood. 2025;145:2788\u201393.","journal-title":"Blood"},{"key":"1441_CR23","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood.2023021429","volume":"142","author":"CE Graham","year":"2023","unstructured":"Graham CE, Lee W-H, Wiggin HR, Supper VM, Leick MB, Birocchi F, et al. Chemotherapy-induced reversal of ciltacabtagene autoleucel\u2013associated movement and neurocognitive toxicity. Blood. 2023;142:1248\u201352.","journal-title":"Blood"},{"key":"1441_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/mdc3.14335","volume":"12","author":"AS Wu","year":"2025","unstructured":"Wu AS, Hophing L, Gosse P, Motamed M, Bhella SD, Stewart K, et al. Parkinsonism and bilateral facial palsy after chimeric antigen receptor T-cell therapy. Mov Disord Clin Pract. 2025;12:371\u20134.","journal-title":"Mov Disord Clin Pract"},{"key":"1441_CR25","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1182\/blood-2024-201783","volume":"144","author":"AD Kumar","year":"2024","unstructured":"Kumar AD, Atallah-Yunes SA, Rajeeve S, Abdelhak A, Hashmi H, Corraes A, et al. Delayed neurotoxicity after CAR-T in multiple myeloma: results from a global IMWG Registry. Blood. 2024;144:4758.","journal-title":"Blood"},{"key":"1441_CR26","doi-asserted-by":"publisher","first-page":"7439","DOI":"10.1182\/blood-2022-163827","volume":"140","author":"M Frigault","year":"2022","unstructured":"Frigault M, Rosenblatt J, Dhakal B, Raje N, Cook D, Gaballa MR, et al. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and\/or refractory multiple myeloma. Blood. 2022;140:7439\u201340.","journal-title":"Blood"},{"key":"1441_CR27","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1182\/blood-2024-201080","volume":"144","author":"MR Bishop","year":"2024","unstructured":"Bishop MR, Rosenblatt J, Dhakal B, Raje N, Cook D, Gaballa MR, et al. Phase 1 study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma (RRMM): efficacy and safety with 34-month median follow-up. Blood. 2024;144:4825.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01441-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01441-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01441-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:17:00Z","timestamp":1769098620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01441-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1441"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01441-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.D., A.D., D.C., L.H., H.S., P.K., M.T., T.K., R.W., J.C., M.B., U.Y., E.W., S.G.: no relevant disclosures; K.J.L.: Research funding from Sanofi; R.P.: advisory board role for Sanofi Aventis and Astra Zeneca, research funding from Bristol Myers Squibb Foundation and GlaxoSmithKline; S.C.: honoraria from Sanofi, Ascentage Pharma, Sobi, Legend Biotech, and research funding from Johnson & Johnson, Takeda, C4 Therapeutics, Abbvie, Ascentage Pharma, AstraZeneca; M.G.: personal fees from Ionis\/Akcea, honorarium from Alnylym, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, personal fees for Data Safety Monitoring board from Abbvie & Arcellex, fees from Johnson & Johnson, Honoraria for Astra Zeneca, Medscape, Dava Oncology. Alexion; P.K.: Honoraria: Pharmacyclics, Sanofi, BeiGene, MustangBio, AstraZeneca, AbbVie. Consulting or Advisory Role: Sanofi. Research Funding: Amgen, Takeda, Sanofi, AbbVie, GlaxoSmithKline, Sorrento Therapeutics, Karyopharm Therapeutics, Regeneron, Ichnos Sciences, Bristol Myers Squibb\/Celgene; P.L.B.: Consultant: Oncopeptidfes. Salarius, Radmetrix, Omeros, CellCentric, AbbVie, Pfizer; S.K.: Consulting or Advisory Role: Takeda, Janssen Oncology, Genentech\/Rocher, Abbvie, BMS\/Celgene, Pfizer, Regeneron, Sanofi, K36 Therapeutics; travel, accommodation and expenses: Abbvie, Pfizer; Research funding: Takeda, Abbvie, Novartis, Sanofi, Janssen Oncology, MedImmune, Roche\/Genentech, CARsgen Therapeutics, Allogene Therapeutics, GSK, Regeneron, BMS\/Celgene; S.A.: Consulting or Advisory Role: Takeda, BeiGene, GlaxoSmithKline, Sanofi, Pharmacyclics, BMS, Amgen, Janssen, Regeneron, Cellectar. Research Funding: Pharmacyclics, Janssen Biotech, Cellectar, BMS, Amgen, GlaxoSmithKline, AbbVie, Ascentage Pharma, Sanofi; R.F.: consultancy for AbbVie, Adaptive, Amgen, Apple, BMS\/Celgene, GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron, Sanofi. Scientific advisory board: Caris Life Sciences. Board of directors: Antengene. Patent for FISH in multiple myeloma. A.Z.: patents submitted for DACH1-IgG, PDE10A-IgG, CAMKV-IgG, Tenascin-R-IgG as biomarkers of neurological autoimmunity, received research funding from Roche\/Genetech and Center for MS and Autoimmune Neurology at Mayo Clinic not relevant to this study, Consulted without personal compensation for Alexion pharmaceuticals, steering committee for the KYSA-8 study for autologous CAR-T-19 treatment for SPS; no personal compensation; Y.L.: advisory board role for Janssen, Sanofi, BMS, Regeneron, Genentech, Tessera, Legend, NexT Therapeutics, steering committee for Janssen, Kite\/Gilead, research funding from Janssen, BMS, scientific advisory board for NexImmune, Caribou and data safety monitor board for Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}